EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Inebilizumab for Treatment of IgG4-Related Disease

John H Stone, Arezou Khosroshahi, Wen Zhang, Emanuel Della Torre, Kazuichi Okazaki, Yoshiya Tanaka iD, J Matthias Löhr, Nicolas Schleinitz, Lingli Dong, Hisanori Umehara, Marco Lanzillotta, Zachary S Wallace und 13 weitere

New England Journal of Medicine · 27.03.2025 · 392 (12) · 1168-1177

DOI: 10.1056/nejmoa2409712 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 27.03.2025. Verfasst von John H Stone und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immunoglobulin G4-Related Disease. Die Arbeit wurde bisher 170-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Amgen Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedImmunoglobulin G4-Related DiseaseAgedFemaleHumansMaleMiddle AgedAntigens, CD19B-LymphocytesDouble-Blind MethodGlucocorticoidsImmunoglobulin GInfusions, IntravenousKaplan-Meier EstimateLymphocyte DepletionRemission InductionSymptom Flare UpTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedAntigens, CD19CD19 molecule, humanGlucocorticoidsImmunoglobulin Ginebilizumab

Autor:innen und Institutionen

  • Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston.
  • Division of Rheumatology, Emory University School of Medicine, Atlanta.
  • Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing.
  • Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, IRCCS San Raffaele Scientific Institute, Milan.
  • Department of Internal Medicine, Kansai Medical University Kori Hospital, Osaka, Japan.
  • First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

ORCID-Profile: Yoshiya Tanaka, Daniel Cimbora

Förderung

  • Amgen Foundation

Zitieren

APA

Stone, J. H., Khosroshahi, A., Zhang, W., Della Torre, E., Okazaki, K., Tanaka, Y., Löhr, J. M., Schleinitz, N., Dong, L., Umehara, H., Lanzillotta, M., Wallace, Z. S., Ebbo, M., Webster, G. J., Martinez Valle, F., Nayar, M. K., Perugino, C. A., Rebours, V., Dong, X., …, & MITIGATE Trial Investigators (2025). Inebilizumab for Treatment of IgG4-Related Disease. New England Journal of Medicine, 392(12), 1168-1177. https://doi.org/10.1056/nejmoa2409712

Vancouver

Stone JH, Khosroshahi A, Zhang W, Della Torre E, Okazaki K, Tanaka Y, et al. Inebilizumab for Treatment of IgG4-Related Disease. New England Journal of Medicine. 2025;392(12):1168-1177. doi:10.1056/nejmoa2409712

BibTeX
@article{Stone2025,
  author = {Stone, John H and Khosroshahi, Arezou and Zhang, Wen and Della Torre, Emanuel and Okazaki, Kazuichi and Tanaka, Yoshiya and Löhr, J Matthias and Schleinitz, Nicolas and Dong, Lingli and Umehara, Hisanori and Lanzillotta, Marco and Wallace, Zachary S and Ebbo, Mikael and Webster, George J and Martinez Valle, Fernando and Nayar, Manu K and Perugino, Cory A and Rebours, Vinciane and Dong, Xinxin and Wu, Yanping and Li, Qing and Rampal, Nishi and Cimbora, Daniel and Culver, Emma L and MITIGATE Trial Investigators, MITIGATE Trial Investigators},
  title = {Inebilizumab for Treatment of IgG4-Related Disease},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {12},
  pages = {1168--1177},
  doi = {10.1056/nejmoa2409712}
}
Kostenlos starten →